The Controversy

Non-celiac gluten sensitivity (NCGS) has been one of the most debated topics in gastroenterology for over a decade. On one side: millions of people worldwide who report significant improvement in digestive, neurological, and systemic symptoms when they remove gluten from their diet, despite testing negative for celiac disease. On the other: sceptics who argue that the symptoms are psychosomatic, attributable to FODMAPs rather than gluten, or simply a nocebo effect.

The truth, as the evidence now stands, is more nuanced than either camp acknowledges. NCGS appears to be a real, biologically measurable condition, though its mechanisms differ from celiac disease and its boundaries remain debated.

What We Know For Certain

Double-Blind, Placebo-Controlled Evidence

The gold standard for proving a food reaction is the double-blind, placebo-controlled food challenge (DBPCFC). Several rigorous DBPCFC studies have now confirmed that a subset of individuals without celiac disease experience reproducible symptoms when given gluten versus placebo. These are not people who know they are eating gluten; they genuinely cannot distinguish between the gluten and placebo capsules. When they receive gluten, they develop symptoms. When they receive placebo, they do not.

A 2023 systematic review of DBPCFC studies estimated that approximately 16% of self-reported gluten-sensitive individuals have reproducible, placebo-controlled reactions to gluten. This number is lower than the total claiming sensitivity, but it represents millions of people worldwide with a genuine, measurable condition.

Biological Markers Have Been Found

A landmark 2016 study by Uhde et al. published in Gut identified measurable biological differences in NCGS patients:

  • Elevated serum markers of intestinal cell damage (FABP2) — indicating acute intestinal epithelial injury after gluten exposure
  • Elevated lipopolysaccharide-binding protein (LBP) — indicating systemic immune activation from gut-derived bacterial products
  • Elevated sCD14 — a marker of innate immune activation, distinct from the adaptive immune response seen in celiac disease

These markers normalised on a gluten-free diet and reappeared on gluten challenge. This provided the first objective evidence that NCGS involves measurable gut barrier damage and immune activation.

NCGS is not celiac disease and does not involve the same autoimmune mechanism. But it does involve measurable intestinal barrier damage and innate immune activation triggered by gluten. It is not "all in your head."

The FODMAP Question

A widely cited 2013 study by Biesiekierski et al. found that when FODMAPs were controlled in the diet, gluten-specific effects were difficult to demonstrate. This was interpreted by many as evidence that NCGS was really FODMAP sensitivity in disguise. However, subsequent studies have shown that while FODMAP sensitivity certainly coexists with (and can be confused with) NCGS, a subset of patients react specifically to gluten proteins independent of FODMAP content. The two conditions overlap but are not identical.

Wheat contains both gluten proteins and fructans (a FODMAP). For some individuals, the problem is fructans; for others, it is gluten; for many, it is both. Distinguishing between them requires careful, controlled testing.

Who Actually Has NCGS?

Diagnosing NCGS currently requires a process of exclusion:

  • Celiac disease must be ruled out through serology (while eating gluten) and, ideally, duodenal biopsy
  • Wheat allergy must be ruled out through IgE testing
  • Symptoms must improve on a gluten-free diet
  • Symptoms must return on blinded gluten reintroduction

There is no single diagnostic test for NCGS, which is one reason the condition remains controversial. The Salerno Experts' Criteria propose a standardised double-blind, placebo-controlled crossover challenge as the diagnostic gold standard, but this is impractical in routine clinical practice.

The Gut Health Dimension

An important question is whether NCGS is a fixed condition or a consequence of impaired gut health. Some researchers propose that NCGS may develop when intestinal permeability is increased: gluten triggers zonulin release, which further opens tight junctions, allowing gluten peptides and bacterial endotoxins to activate the innate immune system. In this model, healing the gut barrier might restore gluten tolerance in some NCGS patients.

This hypothesis is supported by clinical observations that some patients with NCGS eventually tolerate small amounts of gluten after a period of gut healing — unlike celiac patients, who must avoid gluten permanently.

Practical Recommendations

  • Get tested for celiac disease first — before removing gluten. Once gluten is removed, celiac testing becomes unreliable
  • If celiac is ruled out — try a structured 4-6 week gluten elimination followed by controlled reintroduction to assess your personal response
  • Consider FODMAP overlap — a low-FODMAP trial alongside gluten elimination can help distinguish between the two
  • Work on gut health simultaneously — if NCGS is partly a gut permeability issue, healing the barrier may expand your dietary tolerance over time

GutIQ evaluates digestive symptoms, dietary reaction patterns, and gut function indicators to help determine whether your symptoms are more consistent with celiac disease, NCGS, FODMAP sensitivity, or another condition. Getting the right diagnosis directs you to the right solution.